news
Amgen and AstraZeneca highlight data to be presented at 22nd congress of the European Academy of Dermatology and Venereology
3 October 2013 | By Amgen
"The Phase 2 data demonstrate that the primary and secondary end points were met..."
List view / Grid view
Amgen
news
Amgen successfully completes Onyx pharmaceuticals tender offer
1 October 2013 | By Amgen
"Amgen's acquisition of Onyx fits perfectly with our commitment to advancing medicines for cancer patients around the world..."
news
Amgen presents new data from phase 3 study of Talimogene Laherparepvec in patients with metastatic melanoma
30 September 2013 | By Amgen
"These results further support the primary analysis reported at ASCO which demonstrated a statistically significant durable response rate..."
news
Phase 3 trial comparing Vectibix® (panitumumab) to Erbitux® (cetuximab) meets primary endpoint of non-inferiority of overall survival
28 September 2013 | By Amgen
Trial evaluated nearly 1,000 patients with metastatic colorectal cancer...
news
Amgen And ShanghaiTech University announce plans for R&D center
25 September 2013 | By Amgen
Amgen And ShanghaiTech University agree plans for Amgen to open a China research and development (R&D) center at ShanghaiTech University...
news
Amgen and Onyx Pharmaceuticals announce early termination of HSR waiting period
18 September 2013 | By Amgen
Amgen and Onyx Pharmaceuticals have announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in connection with Amgen's proposed acquisition of Onyx, was terminated early on Sept. 18, 2013...
news
Analysis published in New England Journal of Medicine highlights discovery of new predictive biomarkers for Vectibix® (panitumumab)
11 September 2013 | By Amgen
Study links RAS mutations to Vectibix clinical response in patients with metastatic colorectal cancer...
news
Amgen and Cytokinetics announce the first presentation of data from Phase 2 ATOMIC-AHF study of Omecamtiv Mecarbil
3 September 2013 | By Amgen
First trial to evaluate cardiac myosin activator in patients with acute heart failure presented at ESC Congress 2013...
news
Amgen presents pooled analysis showing AMG 145 significantly reduced LDL Cholesterol in over 1,200 patients
1 September 2013 | By Amgen
Results of analyses presented at ESC Congress 2013...
news
Amgen to highlight new data at upcoming ESC Congress 2013
27 August 2013 | By Amgen
Amgen will present new data on omecamtiv mecarbil, a small molecule cardiac myosin activator that is being studied for the treatment of heart failure in collaboration with Cytokinetics...
news
Amgen to acquire Onyx Pharmaceuticals for $125 per share in cash
25 August 2013 | By Amgen
Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash...
news
Amgen and Servier complete product collaboration transaction
12 August 2013 | By Amgen
Amgen and Servier announced the early termination of the waiting period under the Hart–Scott–Rodino Antitrust Improvements Act of 1976 in connection with the cardiovascular product collaboration agreement...
news
The Lancet Oncology publishes results of XGEVA® (denosumab)
16 July 2013 | By Amgen
Phase 2 study reports safety and efficacy results in patients with giant cell tumor of bone...
news
Amgen and Servier announce product collaboration
9 July 2013 | By Amgen
Amgen obtains US rights to novel EU-approved cardiovascular therapy; Servier receives option for omecamtiv mecarbil in Europe...
news
FDA approves Amgen’s XGEVA® (denosumab) for the treatment of giant cell tumor of bone
13 June 2013 | By Amgen
XGEVA becomes first FDA-approved treatment for this rare disease...
